clinical trial · NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 1,000
Triple Negative Breast NeoplasmsSacituzumab tirumotecanPembrolizumabRescue MedicationPaclitaxelNab-paclitaxelGemcitabineCarboplatin
brief summary
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
started
Mar 16, 2025
primary completion
May 18, 2030
completion
May 18, 2030
last updated
Apr 20, 2026
official title
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol